A Sonidegib Experience in the Treatment of Basal Cell Carcinoma with Systemic Lupus Erythematosus: A Case Report

Basal Cell Carcinoma (BCC), a prevalent skin cancer originating from keratinocytes, is mainly caused by the malfunctioning of the Hedgehog (Hh) signaling pathway. Surgical removal stands as the primary treatment, while non-invasive remedies encompass treatments like topical drug therapy, photodynamic therapy, radiotherapy, and molecular biologics, among others. For patients with locally advanced or metastatic basal cell carcinoma, agents targeting the Hedgehog signaling pathway, like sonidegib, have received approval, especially in cases where the lesion is inoperable or unsuitable for radiotherapy. Lupus erythematosus (LE), an autoimmune disorder, may include skin symptoms (such as discoid lupus erythematosus, DLE) and various systemic forms. Presently, there's a lack of documented clinical use of sonidegib in BCC patients alongside LE, particularly due to its unclear immunomodulatory impact on existing autoimmune diseases. In this report, we present a case involving a BCC patient and systemic lupus erythematosus (SLE), who received sonidegib treatment yielding positive results without simultaneously triggering lupus erythematosus activity.